With a number of countries in Europe opting for policies perceived by the pharmaceutical industry as harmful to innovation, Bayer AG's pharma chief has told Scrip that there could come a time when the firm opts not to launch new medicines in some parts of the continent.
Bayer May Not Launch In Innovation-Unfriendly European Markets
Concerns Growing Over Current Environment
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.